Lu Jiamiao, Lee Jasper, Yuan Eric, Wakefield Devin L, Kanke Matt, Pruitt Danielle, Barreda Jose, Rulifson Ingrid C, Xie Jiansong, Ferbas John, Long Jason, Meade Bryan, Homann Oliver, Guo Wei, Gomes Tina, Zhou Hong, Wu Bin, Cui Jixin, Wang Songli
Precision Biology, Amgen Inc., South San Francisco, CA 94080, USA.
Cardiometabolic Disorders, Amgen Inc., South San Francisco, CA 94080, USA.
Mol Ther Nucleic Acids. 2024 Sep 10;35(4):102335. doi: 10.1016/j.omtn.2024.102335. eCollection 2024 Dec 10.
Small interfering RNAs (siRNAs) hold considerable therapeutic potential to selectively silence previously "undruggable" disease-associated targets, offering new opportunities to fight human diseases. This therapeutic strategy, however, is limited by the inability of naked siRNAs to passively diffuse across cellular membranes due to their large molecular size and negative charge. Delivery of siRNAs to liver through conjugation of siRNA to N-acetylgalactosamine (GalNAc) has been a success, providing robust and durable gene knockdown, specifically in hepatocytes. However, the poor delivery and silencing efficacy of siRNAs in other cell types has hindered their applications outside the liver. We previously reported that a genome-wide pooled knockout screen identified as a major modulator of GalNAc-siRNA conjugates. Herein, we demonstrate knockout/knockdown efficaciously enhances siRNA-mediated gene silencing in hepatic and extrahepatic cell lines and . Our results reveal a mechanism by which retrograde Golgi-endoplasmic reticulum (ER) transport and the intracellular lipid droplets (LDs) positively regulate siRNA-mediated gene silencing.
小干扰RNA(siRNAs)具有相当大的治疗潜力,能够选择性地沉默以前“难以成药”的疾病相关靶点,为对抗人类疾病提供了新的机会。然而,这种治疗策略受到限制,因为裸露的siRNAs由于其大的分子尺寸和负电荷而无法被动扩散穿过细胞膜。通过将siRNA与N-乙酰半乳糖胺(GalNAc)偶联将siRNAs递送至肝脏已取得成功,特别是在肝细胞中提供了强大而持久的基因敲低。然而,siRNAs在其他细胞类型中的递送和沉默效率不佳阻碍了它们在肝脏以外的应用。我们之前报道过,全基因组汇集敲除筛选确定 为GalNAc-siRNA偶联物的主要调节因子。在此,我们证明敲除/敲低有效地增强了肝和肝外细胞系中siRNA介导的基因沉默以及 。我们的结果揭示了一种机制,通过该机制逆行高尔基体-内质网(ER)转运和细胞内脂滴(LDs)正向调节siRNA介导的基因沉默。